403,691 Shares in Viemed Healthcare, Inc. $VMD Purchased by Raffles Associates LP

Key Points

• Raffles Associates LP acquired 403,691 Viemed Healthcare shares worth approximately $4.6 million, giving it a 1.06% stake and making VMD its eighth-largest holding. Institutional investors and hedge funds collectively own 74.24% of the company.
• Analyst sentiment is mixed: one firm rates VMD “Buy,” three rate it “Hold,” and the average price target is $14.00. Recent rating changes included downgrades from “Strong Buy” or “Buy” to more cautious recommendations.
• Viemed reported quarterly EPS of $0.07, below the $0.12 consensus estimate, while revenue of $78.1 million slightly exceeded forecasts. Shares opened at $9.10, compared with a 12-month range of $6.05 to $12.61.

Raffles Associates LP acquired a new position in shares of Viemed Healthcare, Inc. (NASDAQ:VMD - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 403,691 shares of the company's stock, valued at approximately $4,602,000. Viemed Healthcare makes up 4.2% of Raffles Associates LP's holdings, making the stock its 8th largest position. Raffles Associates LP owned 1.06% of Viemed Healthcare at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. State of Alaska Department of Revenue acquired a new stake in shares of Viemed Healthcare in the fourth quarter worth approximately $25,000. Kemnay Advisory Services Inc. purchased a new position in Viemed Healthcare in the 4th quarter valued at $46,000. Quarry LP purchased a new position in Viemed Healthcare in the 3rd quarter valued at $48,000. Globeflex Capital L P acquired a new stake in Viemed Healthcare during the 2nd quarter worth $86,000. Finally, Legal & General Group Plc acquired a new stake in Viemed Healthcare during the 2nd quarter worth $97,000. Institutional investors and hedge funds own 74.24% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on VMD shares. Freedom Capital downgraded shares of Viemed Healthcare from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 5th. Weiss Ratings downgraded shares of Viemed Healthcare from a "buy (b-)" rating to a "hold (c+)" rating in a report on Monday, August 17th. Barrington Research assumed coverage on Viemed Healthcare in a research report on Monday. They issued an "outperform" rating and a $14.00 price target for the company. Finally, Wall Street Zen downgraded Viemed Healthcare from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 15th. One equities research analyst has rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Viemed Healthcare has an average rating of "Hold" and an average price target of $14.00.

Insider Activity

In other Viemed Healthcare news, insider William Frazier sold 10,000 shares of the company's stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $11.72, for a total value of $117,200.00. Following the transaction, the insider owned 73,214 shares of the company's stock, valued at $858,068.08. This represents a 12.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Timothy Smokoff sold 20,000 shares of Viemed Healthcare stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $11.50, for a total transaction of $230,000.00. Following the sale, the director owned 75,518 shares of the company's stock, valued at approximately $868,457. This represents a 20.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 20.60% of the stock is currently owned by insiders.

Viemed Healthcare Price Performance

Shares of VMD stock opened at $9.10 on Wednesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.13 and a quick ratio of 1.02. The company has a market capitalization of $346.62 million, a PE ratio of 25.28 and a beta of 1.10. The firm's 50-day moving average is $10.92 and its two-hundred day moving average is $9.89. Viemed Healthcare, Inc. has a 12 month low of $6.05 and a 12 month high of $12.61.

Viemed Healthcare (NASDAQ:VMD - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.05). The business had revenue of $78.10 million during the quarter, compared to analyst estimates of $78.00 million. Viemed Healthcare had a net margin of 4.81% and a return on equity of 10.16%. Analysts predict that Viemed Healthcare, Inc. will post 0.42 earnings per share for the current year.

Viemed Healthcare Profile

Viemed Healthcare, Inc NASDAQ: VMD is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.

Want to see what other hedge funds are holding VMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viemed Healthcare, Inc. (NASDAQ:VMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source